Year: 2003
Type: review
Abstract: he management of motor neurone disease (MND) has evolved rapidly over the last two decades.Although still incurable, MND is not untreatable.From an attitude of nihilism, treatments and interventions that prolong survival have been developed.These treatments do not, however, arrest progression or reverse weakness.They raise difficult practical and ethical questions about quality of life, choice, and end of life decisions.Coordinated multidisciplinary care is the cornerstone of management and evidence supporting this approach, and for symptomatic treatment, is growing.[1][2][3] Hospital based, community rehabilitation teams and palliative care teams can work effectively together, shifting emphasis and changing roles as the needs of the individuals affected by MND evolve.In the UK, MND care centres and regional networks of multidisciplinary teams are being established.Similar networks of MND centres exist in many other European countries and in North America.Here, we review current practice in relation to diagnosis, genetic counselling, the relief of common symptoms, multidisciplinary care, the place of gastrostomy and assisted ventilation, the use of riluzole, and end of life issues.TERMINOLOGY c c Motor neurone disease (MND) is a synonym for amyotrophic lateral sclerosis (ALS).c MND comprises several syndromes (classical or Charcot ALS; progressive bulbar palsy-PBP; progressive muscular atrophy-PMA).c With the exception of primary lateral sclerosis (PLS) all these share the characteristic pathology of MND.The same applies to the ''flail arm'' and ''flail leg'' syndromes (table 1).c MND is used throughout this article, except in relation to the El Escorial criteria. DIAGNOSIS: MAKING IT AND BREAKING ITThe average delay from onset of symptoms to diagnosis is about 14 months, about one third of expected survival.Occasionally, survival following diagnosis may be less than six months.The patient may already suspect the diagnosis and may have visited internet sites or have seen television programmes about people with MND choking to death or demanding the right to assisted suicide.Nevertheless, uncertainty is generally worse than knowing the diagnosis.A diagnosis is usually required before care can be organised.People with suspected MND should be ''fast-tracked'' through the health system to avoid frustrating delays.When the patient is seen for the first time, the diagnosis may be obvious.This poses a dilemma.Should the patient be told, or should one wait until the investigations have been completed?If the individual knows or suspects the diagnosis, it may be best to discuss the possibility of MND, outlining how and when the uncertainty will be resolved.The next step is to exclude other diagnoses (table 2) including rare ''MND mimic'' syndromes (table 3).The El Escorial criteria 4 (box 1) were designed as research diagnostic criteria for clinical trials.Although the criteria strive to codify the process of clinical decision making, patients do not appreciate a diagnosis of ''possible'' or ''probable'' MND.The El Escorial categories of possible and probable ALS (MND) are highly predictive of necropsy proven MND. 5 Thus clinicians can be confident in the diagnosis providing that all the appropriate tests have been done.Routine blood tests are required to exclude other conditions.Examination of the spinal fluid is usually unhelpful, although the total protein may be a little raised.The presence of a significantly raised protein or cell count suggests the need for further investigation to exclude an ALS mimic, such as meningeal infiltration with lymphoma, or (in LMN syndromes) a motor variant of chronic inflammatory demyelinating neuropathy (CIDP).Up to 30% of people in whom MND is diagnosed initially may have other conditions, although in specialist neurological practice the figure is probably about 10%.6 7 Conditions most fre- quently misdiagnosed as MND (table 3) include cervical spondylotic radiculomyelopathy, iv32 www.jnnp.com
Institutions: King's College London, King's College Hospital
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: motor neuron disease, amyotrophic lateral sclerosis, diagnosis, genetic counseling, symptom management, multidisciplinary care, gastrostomy, respiratory support, riluzole, end-of-life decisions, palliative care, progressive bulbar palsy, progressive muscular atrophy, primary lateral sclerosis, El Escorial criteria, prognosis, quality of life
Open Access status: bronze
OpenAlex ID: W2126734293
